Difference between revisions of "Part:BBa K5185028"
(2 intermediate revisions by the same user not shown) | |||
Line 16: | Line 16: | ||
===Results=== | ===Results=== | ||
− | We assembled HNP1 mutants onto CBM3-SUMO-Defensins modules for | + | We assembled HNP1 mutants onto CBM3-SUMO-Defensins modules for characterization(<partinfo>BBa_K51850010</partinfo> <partinfo>BBa_K51850011</partinfo> <partinfo>BBa_K51850012</partinfo> <partinfo>BBa_K51850013</partinfo>) SDS-PAGE electrophoresis identified the expression of HNP1Ala, HNP1AWW and HNP1AWK, and we used them for subsequent antibacterial tests(Fig.1A). |
<html> | <html> | ||
Line 22: | Line 22: | ||
width: 60%;height: 60%;" src="https://static.igem.wiki/teams/5185/part-org/modeling-1.png" text-align="center"><div></html> | width: 60%;height: 60%;" src="https://static.igem.wiki/teams/5185/part-org/modeling-1.png" text-align="center"><div></html> | ||
<br>Figure 1 (A) Sequence of HNP1Ala (B) SDS-PAGE analysis of the recombinant defensins expression in E. coli SHuffle T7 | <br>Figure 1 (A) Sequence of HNP1Ala (B) SDS-PAGE analysis of the recombinant defensins expression in E. coli SHuffle T7 | ||
− | |||
<html> | <html> | ||
<img style="display: block; | <img style="display: block; | ||
Line 30: | Line 29: | ||
The results show that the MIC99 values of the four mutants are all higher than the original version(<partinfo>BBa_K5185000</partinfo>), which means that the point mutations on these amino acids of HNP1 reduce the ability to inhibit Staphylococcus aureus, but the antibacterial activity is not completely lost, and the mutations produce new slightly active substances. Weak HNP1 needs further verification of its antibacterial activity against other pathogenic bacteria. | The results show that the MIC99 values of the four mutants are all higher than the original version(<partinfo>BBa_K5185000</partinfo>), which means that the point mutations on these amino acids of HNP1 reduce the ability to inhibit Staphylococcus aureus, but the antibacterial activity is not completely lost, and the mutations produce new slightly active substances. Weak HNP1 needs further verification of its antibacterial activity against other pathogenic bacteria. | ||
However, since protein engineering has diverse applications, our project serves as a promising model for future teams. For example, even though antibacterial activity is reduced, new characteristics are being attributed to HNP-1. When the purpose is changed to, for example, adding aromatic ring structures to form new interactions, our design proves to be successful while maintaining most antibacterial functions. | However, since protein engineering has diverse applications, our project serves as a promising model for future teams. For example, even though antibacterial activity is reduced, new characteristics are being attributed to HNP-1. When the purpose is changed to, for example, adding aromatic ring structures to form new interactions, our design proves to be successful while maintaining most antibacterial functions. | ||
− | |||
<!-- --> | <!-- --> |
Latest revision as of 06:37, 2 October 2024
HNP1_G12A_Y22A
HNP1Ala is a modified version of HNP1 through substitution of glycine and tryosine with alanine at the 12th residue and 22nd residue, which is expected to increase the hydrophobicity of HNP1.
Usage and Biology
α-defensins typically have a triple-stranded beta-sheet structure based on internal disulfide bonds (Lehrer et al. 2012) and further stabilized by other immutable structures. Apart from these residues, point mutations on alpha-defensins tend to have limited effect on the general conformation. Alpha-defensin dimers are formed when amino acids on the second beta-strand interact with each other. Specifically, carboxyl and nitric groups in the amino acid backbone of the two monomers formed 4 hydrogen bonds during dimerization. In addition, cationicity and hydrophobicity are both key determinants in dimerization rates, with the latter showing more significant impact than the former (Rajabi et al. 2012). Thus, our general goal is to create a stable dimer structure while increasing cationicity and hydrophobicity.
Modeling
Our models can mainly be categorized in active site amino acid mutations and other amino acid mutations. We sought to stabilize the active site by introducing additional interactions between the two monomers. Upon considerations, we decided attempt creating pi-pi, pi-cation, and hydrogen bonding interactions between amino acid side chains. Aromatic rings composes of conjugate pi-bonds, which causes the pi-electrons to be delocalized and shared across multiple molecules. A pi-pi interaction is when the delocalized electrons are shared between two aromatic rings when placed adjacently, while pi-cation interaction is characterized by an attraction between a positively group and the delocalized pi-electrons. It should be noted that mutagenesis in our models might not accurately reflect the actual configuration of side chain of the modified HNP-1 that are produced in experimentation. Therefore, we would prioritize pi-pi interactions (increase hydrophobicity) and pi-cation (increase hydrophobicity and cationicity) over hydrogen bonding under the same predicted affinity. The tetramer of HNP-1 was obtained from the Protein Data Bank (PDB id: 3GNY), and the dimer molecule was extracted. The amino acids of the active site are T-18, C-19, and I-20 (Amino acid - index), and as C-19 is immutable (as discussed later), we will focus on mutating T-18 and I-20. Apart from active site amino acids, other amino acids were also mutated to increase hydrophobicity. It is important to note that there are several immutable that constructs the basic structure of alpha-defensin, namely the cytosine residues (C-2, C-4, C-9, C-19, C-29, C-30) that constitute disulfide bonds, arginine and glutamic acid residues (R-5, E-13) that constitute an essential salt bridge, and an invariant glycine (G-17). Of the remaining amino acids, we selected all non-positive hydrophilic amino acids and mutated them to alanine to increase hydrophobicity without drastically changing the general conformation. Therefore, in this mutation, we first mutated G12 and Y22 to Ala to enhance the hydrophobicity of defensins(Fig. 1A), thus generating the HNP1 mutant HNP1_G12A_Y22A (HNP1Ala).After the alanine substitution of amino acids, the alpha-fold predicted model shows high similarity with the original HNP-1 when aligned in PyMOL (rmsd = 0.482). Hdock result of the final structure HNP-1_Ala gives a confidence score of 0.8058. We then performed point mutations on amino acids G18 and L20 of the active site to obtain three other HNP1 mutants:HNP1ANF,HNP1AWW(BBa_K5185030) and HNP1AWK(BBa_K5185031).
Results
We assembled HNP1 mutants onto CBM3-SUMO-Defensins modules for characterization(No part name specified with partinfo tag. No part name specified with partinfo tag. No part name specified with partinfo tag. No part name specified with partinfo tag.) SDS-PAGE electrophoresis identified the expression of HNP1Ala, HNP1AWW and HNP1AWK, and we used them for subsequent antibacterial tests(Fig.1A).
Figure 1 (A) Sequence of HNP1Ala (B) SDS-PAGE analysis of the recombinant defensins expression in E. coli SHuffle T7
Figure 2: The antibacterial activity of HNP1 mutants. Panels A, B, and C display the 12-hour growth curves (left) and 8-hour minimum inhibitory concentration (MIC) determinations (right) for various mutants. CBM3-sumo↓HNP1Ala is shown in Panel B. HNP1Ala still displayed antimicrobial activity despite being not as efficient as HNP1.
The results show that the MIC99 values of the four mutants are all higher than the original version(BBa_K5185000), which means that the point mutations on these amino acids of HNP1 reduce the ability to inhibit Staphylococcus aureus, but the antibacterial activity is not completely lost, and the mutations produce new slightly active substances. Weak HNP1 needs further verification of its antibacterial activity against other pathogenic bacteria. However, since protein engineering has diverse applications, our project serves as a promising model for future teams. For example, even though antibacterial activity is reduced, new characteristics are being attributed to HNP-1. When the purpose is changed to, for example, adding aromatic ring structures to form new interactions, our design proves to be successful while maintaining most antibacterial functions.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]